Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chief commercial officer
Biotech
Dyne shakes up C-suite after hazy DMD data drop
Dyne Therapeutics has revealed new phase 1/2 data on its Duchenne muscular dystrophy therapy DYNE-251, including several serious TEAEs.
Fraiser Kansteiner
Sep 3, 2024 11:49am
Catalyst Clinical keeps change coming with new CCO
Aug 12, 2024 12:31pm
Merck chief patient officer leaving for NIH—Chutes & Ladders
Mar 4, 2022 9:30am
Califf returns as FDA chief with Senate nod—Chutes & Ladders
Feb 18, 2022 9:30am
